Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analyses from the INBUILD Trial

Autor:	M.R.J. Kolb, K.R. Flaherty, R.S. Silva, A. Prasse, N.M. Patel, C. Vancheri, M. Quaresma, R.-G. Goeldner, S. Stowasser, R. Schlenker-Herceg, A.U. Wells, null on behalf of the INBUILD trial investigators
Rok vydání:	2020
Předmět:	chemistry.chemical_compound medicine.medical_specialty Lung medicine.anatomical_structure chemistry business.industry Internal medicine Medicine Nintedanib In patient business Gastroenterology
Zdroj:	C22. ILD THERAPY III.
DOI:	10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4555
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d421367e535a702916be0a5fdc33dbd1 https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4555 Zobrazit plný text záznamu